Literature DB >> 32024699

TRIM25 Promotes TNF-α-Induced NF-κB Activation through Potentiating the K63-Linked Ubiquitination of TRAF2.

Yuchun Liu1, Kunpeng Liu2, Yingqi Huang2, Meng Sun1, Qingnan Tian3, Shoutao Zhang3, Yunfei Qin4.   

Abstract

As an important effector in response to various intracellular or extracellular stimuli, the NF-κB family extensively participates in a wide spectrum of biological events, and its dysregulation may result in many pathological conditions, such as microbial infection, tumor progression, and neurodegenerative disorders. Previous investigations showed that multiple types of ubiquitination play critical roles in the modulation of the NF-κB signaling pathway, yet the molecular mechanisms are still poorly understood. In the current study, we identified TRIM25, an E3 ubiquitin ligase, as a novel positive regulator in mediating NF-κB activation in human embryonic kidney 293T (HEK293T), HeLa cells, THP-1 cells, and PBMCs. The expression of TRIM25 promoted TNF-α-induced NF-κB signaling, whereas the knockdown had the opposite effect. Furthermore, TRIM25 interacted with TRAF2 and enhanced the K63-linked polyubiquitin chains attached to TRAF2. Moreover, TRIM25 bridged the interaction of TRAF2 and TAK1 or IKKβ. To our knowledge, our study has identified a previously unrecognized role for TRIM25 in the regulation of NF-κB activation by enhancing the K63-linked ubiquitination of TRAF2.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32024699     DOI: 10.4049/jimmunol.1900482

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  TRIMs: selective recruitment at different steps of the NF-κB pathway-determinant of activation or resolution of inflammation.

Authors:  Milton Roy; Rajesh Singh
Journal:  Cell Mol Life Sci       Date:  2021-07-20       Impact factor: 9.261

2.  Tripartite motif-containing 25 facilitates immunosuppression and inhibits apoptosis of glioma via activating NF-κB.

Authors:  Mao-Xu Ge; Yi-Kang Shi; Dong Liu
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-20

3.  Alizarin, a nature compound, inhibits the growth of pancreatic cancer cells by abrogating NF-κB activation.

Authors:  Zihang Xu; Yifei Hou; Chunpu Zou; Haibin Liang; Jiasheng Mu; Xiaoning Jiao; Yangzhuangzhuang Zhu; Lin Su; Mingxi Liu; Xiao Chen; Chunmei Qian; Xiandan Zhu; Wei Gong; Qian Dong; Fei Zhang
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

4.  Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection.

Authors:  Marisol Salgado-Albarrán; Erick I Navarro-Delgado; Aylin Del Moral-Morales; Nicolas Alcaraz; Jan Baumbach; Rodrigo González-Barrios; Ernesto Soto-Reyes
Journal:  NPJ Syst Biol Appl       Date:  2021-05-24

Review 5.  Contributions of Ubiquitin and Ubiquitination to Flaviviral Antagonism of Type I IFN.

Authors:  Erika Hay-McCullough; Juliet Morrison
Journal:  Viruses       Date:  2021-04-27       Impact factor: 5.048

6.  TRIM47 is a novel endothelial activation factor that aggravates lipopolysaccharide-induced acute lung injury in mice via K63-linked ubiquitination of TRAF2.

Authors:  Yisong Qian; Ziwei Wang; Hongru Lin; Tianhua Lei; Zhou Zhou; Weilu Huang; Xuehan Wu; Li Zuo; Jie Wu; Yu Liu; Ling-Fang Wang; Xiao-Hui Guan; Ke-Yu Deng; Mingui Fu; Hong-Bo Xin
Journal:  Signal Transduct Target Ther       Date:  2022-05-06

7.  The cytokines interleukin-6 and interferon-α induce distinct microglia phenotypes.

Authors:  Phillip K West; Andrew N McCorkindale; Boris Guennewig; Thomas M Ashhurst; Barney Viengkhou; Emina Hayashida; So Ri Jung; Oleg Butovsky; Iain L Campbell; Markus J Hofer
Journal:  J Neuroinflammation       Date:  2022-04-16       Impact factor: 9.587

Review 8.  Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class.

Authors:  Francesca D'Amico; Rishov Mukhopadhyay; Huib Ovaa; Monique P C Mulder
Journal:  Chembiochem       Date:  2021-03-18       Impact factor: 3.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.